uveal melanoma: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by dreye

uveal melanoma Introduction (What it is)

uveal melanoma is a cancer that starts inside the eye in a layer called the uvea.
It develops from pigment-producing cells (melanocytes) and can affect vision.
It is most often discussed in ophthalmology, eye oncology, and retinal care settings.
It is commonly identified during a dilated eye exam or imaging done for a suspicious spot in the eye.

Why uveal melanoma used (Purpose / benefits)

In clinical practice, the term uveal melanoma is used to describe a specific diagnosis that guides evaluation, treatment planning, and long-term follow-up. The purpose of identifying uveal melanoma is not only to name the condition, but to determine key features that affect management—such as tumor location, size, growth behavior, and potential risk of spread outside the eye (metastasis).

Benefits of accurate recognition and classification include:

Clarifying what the lesion is: Many intraocular pigmented lesions are benign (non-cancerous), such as a choroidal nevus (often described as a “freckle” inside the eye). Distinguishing a nevus from uveal melanoma helps set appropriate next steps.
Supporting eye- and vision-preserving care when possible: Many modern approaches aim for local tumor control while attempting to preserve the eye, though outcomes vary by clinician and case.
Reducing uncertainty with structured monitoring: When a lesion is indeterminate, consistent documentation and imaging help detect meaningful change over time.
Enabling staging and risk assessment: Uveal melanoma care often includes assessing whether the tumor is limited to the eye and evaluating factors linked to metastatic risk. The specific approach varies by clinician and case.
Planning follow-up: Even after local treatment, uveal melanoma typically requires ongoing ophthalmic follow-up and systemic surveillance plans coordinated with appropriate specialists.

Indications (When ophthalmologists or optometrists use it)

Clinicians consider uveal melanoma in scenarios such as:

A new or changing pigmented intraocular lesion seen on dilated exam
Documented growth of a known choroidal nevus or other uveal lesion
Symptoms that can occur with intraocular tumors, such as blurred vision, flashes, floaters, or a visual field defect (symptoms are non-specific and can occur in many eye conditions)
A suspicious lesion noted on routine imaging (for example, fundus photography, OCT, or ultrasound)
A lesion associated with subretinal fluid, orange pigment, or other features that raise concern (interpretation varies by clinician and case)
An iris mass or visible change in iris appearance that prompts evaluation for iris melanoma versus benign lesions
Work-up of unexplained retinal detachment, ocular inflammation, or elevated eye pressure when an underlying mass is a consideration (less common, depends on presentation)

Contraindications / when it’s NOT ideal

Because uveal melanoma is a diagnosis (not a single procedure), “contraindications” usually relate to when the label is unlikely or when certain diagnostic or treatment approaches may not be appropriate.

Situations where another explanation or approach may be more suitable include:

A stable lesion with long-term documentation consistent with a benign nevus, where continued monitoring may be favored over invasive testing (varies by clinician and case)
Lesions that better fit non-melanoma causes, such as a choroidal hemangioma, inflammatory lesions, or metastasis from another cancer (requires clinician evaluation)
When advanced imaging or biopsy would add limited value compared with careful observation, or when risks outweigh benefits (varies by clinician and case)
When eye-sparing local therapies are unlikely to achieve meaningful tumor control due to tumor size, location, or complications—leading clinicians to consider other approaches (varies by clinician and case)
Medical conditions that make certain interventions (anesthesia, surgery, or radiation planning) higher risk, prompting alternate planning or referral (case-dependent)

How it works (Mechanism / physiology)

High-level mechanism: uveal melanoma arises from melanocytes within the uveal tract. Over time, abnormal cells can multiply and form a tumor. The tumor can affect nearby eye structures, potentially disrupting vision. Unlike many surface eye cancers, uveal melanoma is intraocular (inside the eye), which influences how it is detected and treated.

Relevant eye anatomy: The uvea is the middle layer of the eye and includes:

Iris: the colored front part of the eye that controls pupil size
Ciliary body: produces aqueous humor (the eye’s internal fluid) and helps focus the lens
Choroid: a vascular layer behind the retina that supplies oxygen and nutrients

Most uveal melanomas arise in the choroid, but they can also occur in the ciliary body or iris.

How it can affect vision: Depending on location and size, a tumor may:

Distort or detach the retina (affecting central or peripheral vision)
Cause subretinal fluid that blurs vision
Lead to bleeding, inflammation, or secondary glaucoma (elevated eye pressure) in some cases

Spread (metastasis): uveal melanoma can spread through the bloodstream. The liver is a common site of metastasis discussed in clinical care, but patterns vary by individual case.

Onset/duration/reversibility: These properties don’t apply in the way they would for a medication. Instead, clinicians focus on growth behavior, local control after treatment, and long-term monitoring for recurrence or spread.

uveal melanoma Procedure overview (How it’s applied)

uveal melanoma is not a single procedure; it is a diagnosis managed through a structured evaluation and a range of possible treatments. A typical high-level workflow may include:

Evaluation / exam – Symptom review and eye history – Dilated eye exam to inspect the retina and uveal tract – Baseline documentation of lesion appearance and size
Testing and imaging (to characterize the lesion) – Fundus photography to document appearance – Optical coherence tomography (OCT) to assess the retina and any fluid – Ocular ultrasound to estimate thickness and internal characteristics – Additional imaging may be used in selected cases (varies by clinician and case)
Assessment and differential diagnosis – Clinicians compare features against benign lesions and other tumor types – Decisions may include observation with serial imaging versus treatment planning
Intervention (if treatment is selected) – Options may include radiation-based therapy (such as plaque brachytherapy or proton beam therapy), surgical approaches (including tumor resection in selected cases), or enucleation (removal of the eye) in specific circumstances
– The choice depends on tumor features, eye health, and patient factors (varies by clinician and case)
Immediate checks – Post-intervention eye exams assess comfort, inflammation, pressure, and early complications
Follow-up – Ongoing ophthalmic monitoring for local control and treatment effects – Systemic surveillance planning for metastasis risk, coordinated with appropriate specialists (approaches vary)

Types / variations

uveal melanoma is commonly described in several ways that help clinicians communicate risk, plan care, and standardize follow-up.

By location (anatomical subtype):

Choroidal melanoma: arises in the choroid (behind the retina); often detected on dilated exam or imaging
Ciliary body melanoma: arises in the ciliary body; may be less visible on routine exam and sometimes presents later
Iris melanoma: arises in the iris; may be noticed as a visible spot or change in iris shape or color

By size and extent:

Clinicians may describe tumors as small, medium, or large, or by measured dimensions on imaging. Definitions can vary across guidelines and practices.

By clinical behavior:

Indeterminate lesions: not clearly benign or malignant; managed with careful observation or further testing depending on risk features
Localized disease: confined to the eye
Metastatic disease: spread to other organs; managed with systemic evaluation and therapies coordinated outside ophthalmology

By molecular/genetic features (risk stratification):

Some centers use tumor genetics or gene-expression profiling to estimate metastatic risk. Testing methods and interpretation vary by clinician and case, and availability differs by region.

By management approach (therapeutic variation):

Radiation-based eye-sparing treatment: different modalities exist (equipment, dosing, and planning vary by center)
Surgical approaches: local resection in selected cases; enucleation in others
Systemic management: if metastasis is present, oncology-directed treatments may be considered (options vary and are evolving)

Pros and cons

Pros:

Can provide a clear explanation for a suspicious intraocular mass and related symptoms
Supports structured imaging and documentation for monitoring or treatment planning
Many cases can be managed with eye-sparing approaches, depending on tumor features
Encourages coordinated care between eye specialists and other clinicians when systemic evaluation is needed
Follow-up frameworks help detect local recurrence or treatment-related complications earlier
Risk stratification (when available) can help personalize surveillance discussions

Cons:

It is a serious diagnosis that can carry risk beyond the eye, including metastasis (risk varies)
Treatments can affect vision due to tumor location, retinal involvement, or therapy-related effects
Some interventions involve specialized centers, equipment, or multidisciplinary coordination
Diagnosis may be uncertain in early or borderline cases, requiring time and repeat imaging
Long-term follow-up is commonly needed, which can be burdensome
Emotional impact can be significant for patients and families, even when local control is achieved

Aftercare & longevity

Aftercare for uveal melanoma typically centers on two goals: (1) monitoring the eye for tumor control and treatment effects, and (2) monitoring overall health for signs of spread when relevant. The exact schedule and tests vary by clinician and case.

Factors that commonly affect outcomes and “longevity” of results (such as local tumor control and retained vision) include:

Tumor size and location: Tumors closer to critical structures (like the macula or optic nerve) may have a higher chance of affecting vision, regardless of treatment type.
Baseline eye health: Pre-existing retinal disease, macular degeneration, diabetic retinopathy, or glaucoma can influence visual outcomes.
Treatment modality and planning: Radiation type, surgical approach, and technique details differ by center and can affect side effects.
Treatment-related eye changes: Examples include radiation retinopathy, optic nerve effects, cataract development, dry eye, or pressure changes; not all patients experience these, and severity varies.
Follow-up consistency: Ongoing exams and imaging help clinicians track tumor stability and manage complications when they arise.
Systemic risk profile: Clinical and (when available) molecular features may influence how clinicians plan surveillance for metastasis.

This section is informational and not a substitute for individualized follow-up planning.

Alternatives / comparisons

Because uveal melanoma exists within a spectrum of pigmented eye lesions and tumor behaviors, alternatives often refer to different diagnostic pathways or different treatment strategies rather than a single substitute.

Observation/monitoring vs immediate treatment

Observation may be used for lesions that appear more consistent with a benign nevus or when malignancy is uncertain. This relies on repeat exams and imaging to detect change.
Immediate treatment is more commonly considered when clinical features strongly suggest melanoma or when documented growth is present. The threshold for treatment varies by clinician and case.

Radiation-based eye-sparing therapy vs surgery

Plaque brachytherapy (a radiation source placed near the tumor for a planned time) is commonly discussed for localized tumors suitable for this approach.
Proton beam or other external beam approaches may be used depending on tumor location, size, and local availability.
Local resection (surgical removal of the tumor) may be considered in selected situations and specialized centers.
Enucleation (removal of the eye) may be considered when the tumor is large, painful, associated with severe complications, or when other approaches are less suitable. Decision-making is individualized.

Local eye treatment vs systemic therapy

Local therapies primarily address the tumor in the eye.
If disease is metastatic, care typically shifts toward systemic oncology management. Options may include immunotherapy, targeted therapies, liver-directed approaches, and clinical trials, depending on tumor biology and local practice. Effectiveness and availability vary by clinician and case.

uveal melanoma Common questions (FAQ)

Q: Is uveal melanoma the same as skin melanoma?
No. Both involve melanocytes, but uveal melanoma starts inside the eye in the uveal tract. Risk factors, behavior, and treatment approaches can differ from cutaneous (skin) melanoma.

Q: What parts of the eye can uveal melanoma affect?
It can arise in the choroid, ciliary body, or iris. The effects on vision depend largely on where the tumor is and whether it affects the retina, macula, or optic nerve.

Q: Does uveal melanoma cause pain?
Many cases are painless, especially early on. Pain can occur if there are complications such as inflammation, pressure elevation, or advanced disease, but symptoms vary widely.

Q: How is uveal melanoma diagnosed?
Diagnosis is often based on a dilated eye exam plus imaging such as ultrasound and OCT. Biopsy is used in selected cases for genetic testing or diagnostic uncertainty, but it is not required for every patient (varies by clinician and case).

Q: What treatments are commonly used?
Commonly discussed options include radiation-based therapies (such as plaque brachytherapy or proton beam therapy) and surgical approaches, including enucleation in selected situations. The choice depends on tumor features, eye health, and specialist judgment.

Q: How long do results last after treatment?
Local treatments are generally intended to provide long-term tumor control, but follow-up is still needed to monitor for recurrence and treatment effects. Visual outcomes can change over time due to retinal or optic nerve effects, and this varies by case.

Q: How safe are the treatments?
Treatments are widely used in specialist care, but each has potential risks and side effects. Safety depends on tumor characteristics, the specific modality, and individual health factors; clinicians typically balance local control with vision preservation goals.

Q: Will I be able to drive or use screens during evaluation or after treatment?
During evaluation, dilating drops can temporarily blur vision and increase light sensitivity, which may affect driving the same day. After treatment, visual function depends on baseline vision, tumor location, and treatment effects; recommendations are individualized.

Q: What does follow-up usually involve?
Follow-up often includes repeat eye exams and imaging to confirm stability or tumor response and to watch for complications. Many care plans also include some form of systemic surveillance coordinated with appropriate clinicians, particularly for higher-risk tumors.

Q: How much does evaluation and treatment cost?
Costs vary by country, insurance coverage, facility type, and the treatment selected. Imaging, specialist consultations, radiation planning, surgery, and long-term follow-up can contribute differently depending on the case and care setting.